Eledon Pharmaceuticals (NASDAQ:ELDN) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.57) by 12.28 percent. This is a 233.33 percent decrease over losses of $(0.15) per share from the same period last year.
FARO Technologies Sees Q4 EPS $0.25-$0.45 vs $0.39 Est; Revenue $99.0M-$107.0M vs $102.36M Est
Outlook for the Fourth Quarter 2022
For the fourth quarter ending December 31, 2022, FARO currently expects:
Revenue in the range of $99.0 to $107.0 million
Non-GAAP
